AbCellera Results Presentation Deck

Q1 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 6 TECHNOLOGY DEVELOPMENT: T CELL ENGAGER PLATFORM A DIVERSE PANEL OF CD3 ANTIBODIES TO CREATE NEW CANCER THERAPIES We used our technology to find hundreds of CD3-binding antibodies that can be combined to create precision cancer therapies. We then used our clinically-validated bispecifics platform, OrthoMab™ to pair the CD3-binding antibodies with a single EGFR- binding arm and confirm their function. CD3-binding antibodies Diverse Developable tumor-binding antibodies Validated

View entire presentation